These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

240 related items for PubMed ID: 20890068

  • 1. High efficacy and low toxicity of short-course oral valganciclovir as pre-emptive therapy for hematopoietic stem cell transplant cytomegalovirus infection.
    Saleh AJ, Al Mohareb F, Al Rabiah F, Chaudhri N, Al Sharif F, Al Zahrani H, Mohamed SY, Patel M, Rasheed W, Nurgat Z, Bakr M, Ahmed S, Zaidi S, Nasser A, Ibrahim K, Al Abdely H, Aljurf M.
    Hematol Oncol Stem Cell Ther; 2010; 3(3):116-20. PubMed ID: 20890068
    [Abstract] [Full Text] [Related]

  • 2. Initial low-dose valganciclovir as a preemptive therapy is effective for cytomegalovirus infection in allogeneic hematopoietic stem cell transplant recipients.
    Takenaka K, Nagafuji K, Takase K, Kamimura T, Mori Y, Ito Y, Nishi Y, Henzan H, Kato K, Harada N, Eto T, Miyamoto T, Teshima T, Akashi K.
    Int J Hematol; 2012 Jul; 96(1):94-100. PubMed ID: 22547196
    [Abstract] [Full Text] [Related]

  • 3. Valganciclovir for pre-emptive therapy of cytomegalovirus viraemia after hematopoietic stem cell transplantation: a prospective multi-center trial.
    Liu KY, Wang Y, Han MZ, Huang H, Chen H, Liu QF, Wang JM, Liu T, Song YP, Ma J, Wu DP, Zou P, Huang XJ.
    Chin Med J (Engl); 2010 Aug; 123(16):2199-205. PubMed ID: 20819665
    [Abstract] [Full Text] [Related]

  • 4. Oral valganciclovir as preemptive therapy is effective for cytomegalovirus infection in allogeneic hematopoietic stem cell transplant recipients.
    Takenaka K, Eto T, Nagafuji K, Kamezaki K, Matsuo Y, Yoshimoto G, Harada N, Yoshida M, Henzan H, Takase K, Miyamoto T, Akashi K, Harada M, Teshima T, for Fukuoka Blood and Marrow Transplant Group (FBMTG).
    Int J Hematol; 2009 Mar; 89(2):231-237. PubMed ID: 19148587
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Oral valganciclovir as preemptive therapy for cytomegalovirus infection post allogeneic stem cell transplantation.
    Busca A, de Fabritiis P, Ghisetti V, Allice T, Mirabile M, Gentile G, Locatelli F, Falda M.
    Transpl Infect Dis; 2007 Jun; 9(2):102-7. PubMed ID: 17461994
    [Abstract] [Full Text] [Related]

  • 7. Half-dose ganciclovir preemptive treatment of cytomegalovirus infection after pediatric allogeneic hematopoietic stem cell transplantation.
    Ju HY, Kang HJ, Hong CR, Lee JW, Kim H, Park KD, Shin HY, Park JD, Choi EH, Lee HJ, Ahn HS.
    Transpl Infect Dis; 2016 Jun; 18(3):396-404. PubMed ID: 27041364
    [Abstract] [Full Text] [Related]

  • 8. Valganciclovir is safe and effective as pre-emptive therapy for CMV infection in allogeneic hematopoietic stem cell transplantation.
    Ayala E, Greene J, Sandin R, Perkins J, Field T, Tate C, Fields KK, Goldstein S.
    Bone Marrow Transplant; 2006 May; 37(9):851-6. PubMed ID: 16532016
    [Abstract] [Full Text] [Related]

  • 9. Can low-dose preemptive valganciclovir replace standard intravenous ganciclovir treatment in recipients of allogeneic stem cell transplantation?
    Kaynar L, Metan G, Gökahmetoğlu S, Kurnaz F, Mumcuoğlu H, Öztürk A, Şıvgın S, Pala C, Yıldız O, Eser B, Ünal A, Çetin M.
    J Chemother; 2013 Oct; 25(5):286-91. PubMed ID: 24070136
    [Abstract] [Full Text] [Related]

  • 10. Similar reduction of cytomegalovirus DNA load by oral valganciclovir and intravenous ganciclovir on pre-emptive therapy after renal and renal-pancreas transplantation.
    Kalpoe JS, Schippers EF, Eling Y, Sijpkens YW, de Fijter JW, Kroes AC.
    Antivir Ther; 2005 Oct; 10(1):119-23. PubMed ID: 15751769
    [Abstract] [Full Text] [Related]

  • 11. Pre-emptive therapy against cytomegalovirus (CMV) disease guided by CMV antigenemia assay after allogeneic hematopoietic stem cell transplantation: a single-center experience in Japan.
    Kanda Y, Mineishi S, Saito T, Seo S, Saito A, Suenaga K, Ohnishi M, Niiya H, Nakai K, Takeuchi T, Kawahigashi N, Shoji N, Ogasawara T, Tanosaki R, Kobayashi Y, Tobinai K, Kami M, Mori S, Suzuki R, Kunitoh H, Takaue Y.
    Bone Marrow Transplant; 2001 Feb; 27(4):437-44. PubMed ID: 11313674
    [Abstract] [Full Text] [Related]

  • 12. Occurrence of adverse events caused by valganciclovir as pre-emptive therapy for cytomegalovirus infection after allogeneic stem cell transplantation is reduced by low-dose administration.
    Takahata M, Hashino S, Nishio M, Sugita J, Shigematsu A, Onozawa M, Fujimoto K, Endo T, Kondo T, Tanaka J, Imamura M, Teshima T.
    Transpl Infect Dis; 2015 Dec; 17(6):810-5. PubMed ID: 26354293
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Initial experience with oral valganciclovir for pre-emptive cytomegalovirus therapy after lung transplantation.
    Aigner C, Jaksch P, Winkler G, Czebe K, Taghavi S, Marta G, Klepetko W.
    Wien Klin Wochenschr; 2005 Jul; 117(13-14):480-4. PubMed ID: 16091875
    [Abstract] [Full Text] [Related]

  • 17. Successful conversion to everolimus after cytomegalovirus infection in a heart transplant recipient.
    Imamura T, Shiga T, Kinugawa K, Kato N, Endo M, Inaba T, Maki H, Hatano M, Yao A, Hirata Y, Nagai R.
    Int Heart J; 2012 Jul; 53(3):199-201. PubMed ID: 22790690
    [Abstract] [Full Text] [Related]

  • 18. Efficacy of valganciclovir administered as preemptive therapy for cytomegalovirus disease in liver transplant recipients: impact on viral load and late-onset cytomegalovirus disease.
    Singh N, Wannstedt C, Keyes L, Gayowski T, Wagener MM, Cacciarelli TV.
    Transplantation; 2005 Jan 15; 79(1):85-90. PubMed ID: 15714174
    [Abstract] [Full Text] [Related]

  • 19. Oral Valganciclovir as Preemptive Therapy for Cytomegalovirus Reactivation in Pediatric Hematopoietic Stem Cell Transplant Patients.
    Atay D, Erbey F, Akcay A, Dag A, Ozturk G.
    J Pediatr Hematol Oncol; 2015 Oct 15; 37(7):543-7. PubMed ID: 26207778
    [Abstract] [Full Text] [Related]

  • 20. Sequential treatment of cytomegalovirus infection or disease with a short course of intravenous ganciclovir followed by oral valganciclovir: efficacy, safety, and pharmacokinetics.
    Caldés A, Gil-Vernet S, Armendariz Y, Colom H, Pou L, Niubó J, Lladó L, Torras J, Manito N, Rufí G, Grinyó JM.
    Transpl Infect Dis; 2010 Jun 15; 12(3):204-12. PubMed ID: 20002612
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.